RGNX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

61.72M

+190.92%

-0.638

-36.85%

77.53M

-12.9%

-0.316

-363.33%

52.26M

+144.7%

-0.870

-36.96%

Estimates Revision

The market is revising Downward the revenue expectations for REGENXBIO Inc. (RGNX) for FY2025, with the revenue forecasts being adjusted by -13.96% over the past three months. During the same period, the stock price has changed by 49.35%.

Revenue Estimates for FY2025

Revise Downward

-13.96%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.7%

In Past 3 Month

Stock Price

Go Up

+49.35%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is 24.25 USD with a low forecast of 14.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 13.830

Low

14.00

Averages

24.25

High

37.00

Current: 13.830

Low

14.00

Averages

24.25

High

37.00

Leerink

Mani Foroohar

Outperform

maintain

$16 -> $20

2025-12-15

New

Reason

Leerink

Mani Foroohar

Price Target

$16 -> $20

2025-12-15

New

maintain

Outperform

Reason

Leerink analyst Mani Foroohar raised the firm's price target on Regenxbio (RGNX) to $20 from $16 and keeps an Outperform rating on the shares. Ahead of a busy 2026 catalyst path for Regenxbio, the firm is updating its model to reflect a larger Duchenne muscular dystrophy opportunity following clinical/regulatory setbacks by first-mover Sarepata (SRPT) - opening the door for Regenxbio to differentiate on safety in particular and take meaningful share.

Morgan Stanley

NULL -> Overweight

maintain

$24 -> $25

2025-11-07

Reason

Morgan Stanley

Price Target

$24 -> $25

2025-11-07

maintain

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on Regenxbio to $25 from $24 and keeps an Overweight rating on the shares.

Leerink

Mani Foroohar

Outperform

maintain

2025-08-19

Reason

Leerink

Mani Foroohar

Price Target

2025-08-19

maintain

Outperform

Reason

Leerink analyst Mani Foroohar keeps an Outperform rating on Regenxbio after the company announced the FDA extended its review of clemidsogene lanparvovec for mucopolysaccharidosis II to February 8, 2026, from November 9, 2025. The extension follows submission of longer-term data for all patients in the pivotal study at the FDA's request, the analyst tells investors in a research note. Leerink believes the extension is related as much to the recent turnover at the Center for Biologics Evaluation and Research than it is to specific review issues for Regenxbio. It says the delay is "not a needle mover" and should have a muted impact on the shares.

Barclays

Gena Wang

Overweight

downgrade

$50 -> $37

2025-08-08

Reason

Barclays

Gena Wang

Price Target

$50 -> $37

2025-08-08

downgrade

Overweight

Reason

Barclays analyst Gena Wang lowered the firm's price target on Regenxbio to $37 from $50 and keeps an Overweight rating on the shares following the Q2 report.

RBC Capital

Outperform

NULL

downgrade

$21 -> $17

2025-08-08

Reason

RBC Capital

Price Target

$21 -> $17

2025-08-08

downgrade

Outperform

NULL

Reason

RBC Capital lowered the firm's price target on Regenxbio to $17 from $21 and keeps an Outperform rating on the shares after its Q2 results. In DMD, the company's pivotal trial that may lead to accelerated approval is ongoing, the analyst tells investors in a research note. RBC adds that it continues to like the setup given an undemanding valuation.

Goldman Sachs

Paul Choi

Hold

Maintains

$14 → $12

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$14 → $12

2025-04-17

Maintains

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Regenxbio Inc (RGNX.O) is -5.03, compared to its 5-year average forward P/E of 2.88. For a more detailed relative valuation and DCF analysis to assess Regenxbio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

2.88

Current PE

-5.03

Overvalued PE

23.42

Undervalued PE

-17.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.95

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

6.90

Undervalued EV/EBITDA

-14.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.90

Current PS

0.00

Overvalued PS

9.37

Undervalued PS

2.43

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RGNX News & Events

Events Timeline

No data

News

8.5

11-26SeekingAlpha

Regenxbio submits $300M mixed shelf registration statement

1.0

11-25PRnewswire

REGENXBIO to Participate in Upcoming Investor Conference

9.5

11-09Yahoo Finance

Earnings Report: REGENXBIO Inc. (NASDAQ:RGNX) Releases Results, Analysts Raise Their Projections

People Also Watch

Frequently Asked Questions

What is Regenxbio Inc (RGNX) stock price today?

The current price of RGNX is 13.83 USD — it has decreased -0.29 % in the last trading day.

What is Regenxbio Inc (RGNX)'s business?

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

What is the price predicton of RGNX Stock?

What is Regenxbio Inc (RGNX)'s revenue for the last quarter?

Regenxbio Inc revenue for the last quarter amounts to 29.73M USD, increased 22.88 % YoY.

What is Regenxbio Inc (RGNX)'s earnings per share (EPS) for the last quarter?

Regenxbio Inc. EPS for the last quarter amounts to -1.20 USD, increased 2.56 % YoY.

What changes have occurred in the market's expectations for Regenxbio Inc (RGNX)'s fundamentals?

How many employees does Regenxbio Inc (RGNX). have?

Regenxbio Inc (RGNX) has 353 emplpoyees as of December 16 2025.

What is Regenxbio Inc (RGNX) market cap?

Today RGNX has the market capitalization of 700.12M USD.